On September 10, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported it will present a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development taking place September 25-28, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:
Title: Atebimetinib Reduces Tumor Volume and Preserves Body Mass: A Dual Mechanism for Extended Survival in Pancreatic Cancer
Presenter: Peter Vu, M.D., MHA, UC San Diego Health
Poster Number: A134
Session Date: Saturday, September 26, 2026
Session Time: 6:00 – 8:00 pm PT
Location: Indigo CDCH

The abstract will be available on the AACR (Free AACR Whitepaper) website. Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source

(Press release, Immuneering, SEP 10, 2026, View Source [SID1234670728])